Integrating of Artificial Intelligence in Drug Discovery and Development: A Comparative Study

Abstract

Artificial intelligence (AI) has the potential to revolutionize drug discovery and development by significantly reducing the time and costs involved in bringing new drugs to market. This paper presents a comparative study of non-integrated AI drug discovery and the drug development process with the use of AI. The research examined the discovery and development of several drugs that were developed with the aid of AI, including DSP-1181, Halicin, and Bexion. The objective of the research is to compare traditional drug discovery (without the aid of AI) and the development process to AI-enabled methods in terms of their efficiency, cost-effectiveness, and success rates. The methodology is with VOSviewer of 500 research papers with respect to Drug discovery and development using Artificial Intelligence. The findings suggest that the use of AI in drug discovery and development is advantageous over the non-integration of AI with drug development. These include the ability to identify new drug targets, reduce the time and costs of drug development, and improve the efficiency of clinical trials.